A double‐blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis

Weinshenker, Brian G.; Penman, Merrolee; Bass, B.; Ebers, G. C.; Rice, George P.

doi:10.1212/wnl.42.8.1468

Cited by 144 publications

(60 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, the frequency of the various NPF factors is unknown. As new pharmacological treatments are developed for MS fatigue, [23][24][25][26] differentiation and quantification of these types of fatigue is crucial before beginning clinical trials. Because this preliminary work has not yet been done, therapeutic trials, to date, have included heterogeneous groups of MS patients (with regard to fatigue), suggesting that caution is needed when generalizing the results of these studies.…”

Section: Fatigue Algorithm For Msmentioning

confidence: 99%

Primary and Nonprimary Fatigue in Multiple Sclerosis

Forwell¹,

Brunham²,

Tremlett³

et al. 2008

International Journal of MS Care

View full text Add to dashboard Cite

Using the fatigue algorithm described in the Clinical Practice Guidelines for Fatigue and Multiple Sclerosis (MS), this study aimed to determine the frequency of fatigue related directly to the MS disease process (primary fatigue) versus that related to disease symptoms such as depression (nonprimary fatigue), differentiate primary from nonprimary MS fatigue, and identify any characteristics unique to primary MS fatigue. Consecutive clinically definite MS patients from the University of British Columbia MS clinic were invited to participate. The screening assessment included standardized scales and questionnaires. In total, 50 patients completed the study. Nonprimary fatigue was present in 36 individuals (72%), of whom all but 2 had multiple factors contributing to fatigue. The most common factors contributing to nonprimary fatigue were sleep problems (58%), mobility limitations (52%), and depression (40%). Compared with patients with nonprimary fatigue, those with isolated primary fatigue had lower fatigue scores and reported fatigue onset at midday (P < .05). Any attempt to study or manage MS fatigue should be preceded by identification and amelioration of treatable nonprimary fatigue factors before focusing on primary fatigue in MS.

show abstract

Section: Fatigue Algorithm For Msmentioning

confidence: 99%

Primary and Nonprimary Fatigue in Multiple Sclerosis

Forwell¹,

Brunham²,

Tremlett³

et al. 2008

International Journal of MS Care

View full text Add to dashboard Cite

show abstract

“…Psychostimulant medications, such as methylphenidate, could be effective in treating CRF, as they have been found to produce enhanced alertness, attention, and vigilance, and to reduce fatigue in patients with other chronic conditions, such as multiple sclerosis and HIV infection [59][60][61].…”

Section: Psychostimulantsmentioning

confidence: 99%

Pharmacologic Treatment of Cancer-Related Fatigue

et al. 2007

View full text Add to dashboard Cite

Fatigue is the most commonly reported symptom in patients with cancer, with a prevalence of over 60% reported in the majority of studies. This paper systematically reviews pharmacologic agents in the treatment of cancer-related fatigue (CRF). We conducted a literature review of clinical trials that assessed pharmacologic agents for the treatment of CRF. These agents include hematopoietics (for anemia), corticosteroids, and psychostimulants. Other therapeutic agents that are less well studied for CRF but are currently the focus of clinical trials include l-carnitine, modafinil, bupropion, and selective serotonin reuptake inhibitors such as paroxetine. The Oncologist 2007;12(suppl 1):43-51

show abstract

“…Lower doses (18.5 mg) were not different from placebo, while higher doses (>75 mg) may provoke severe adverse effects like impaired hepatic function, agitation, and sleep disturbances which may lead to drug withdrawal due to side effects [55]. …”

Section: Fatiguementioning

confidence: 99%

Symptomatic Treatment of Multiple Sclerosis

2006

View full text Add to dashboard Cite

Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of life of the affected patients. Moreover, with symptomatic treatment the development of a secondary physical impairment due to an existing one may be avoided. Many therapeutic techniques as well as different drugs are used for the treatment of MS symptoms, but only a few of them have been investigated, especially in MS patients, and are approved by the national health authorities. Despite an overwhelming number of publications, only a few evidence-based studies exist and consensus reports are very rare, too. Therefore, it seemed necessary to develop a consensus statement on symptomatic treatment of MS comprising existing evidence-based literature as well as therapeutic experience of neurologists who have dealt with these problems over a long time. This consensus paper contains proposals for the treatment of the most common MS symptoms: disorders of motor function and coordination, of cranial nerve function, of autonomic, cognitive, and psychological functions as well as MS-related pain syndromes and epileptic seizures.

show abstract

A double‐blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis

Cited by 144 publications

References 0 publications

Primary and Nonprimary Fatigue in Multiple Sclerosis

Primary and Nonprimary Fatigue in Multiple Sclerosis

Pharmacologic Treatment of Cancer-Related Fatigue

Symptomatic Treatment of Multiple Sclerosis

Contact Info

Product

Resources

About